| Description | FAPI-4 FAPI-4 is a fibroblast activating protein (FAP) inhibitor, a FAPI ligand, which shows strong liver uptake in PET imaging of primary liver cancer hepatocellular carcinoma (HCC) and is commonly used in PET imaging for the study of cancer. |
| In vivo | 在接种 HT-1080-FAP 细胞的 8 周龄 BALB/c nu/nu 小鼠中，FAPI-4（每只小鼠 30 nM；静脉注射；一次）能显示出高总体肿瘤摄取率[2]。 |
| Synonyms | DOTA-fapi-04, FAPI 4 |
| molecular weight | 872.92 |
| Molecular formula | C40H54F2N10O10 |
| CAS | 2374782-02-0 |
| Storage | keep away from direct sunlight | store at -20°C | Shipping with blue ice. |
| Solubility | DMSO: 80 mg/mL (91.65 mM), Sonication is recommended. |
| References | 1. Giesel FL, et al. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. 2. Anastasia Loktev, et al. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention. J Nucl Med. 2019 Oct;60(10):1421-1429. |